A. Dose reduction B. High-dose loperamide (4 mg at onset, then 2 mg every 2 hours until diarrhea free) C. Prednisone daily until diarrhea is controlled, then taper D. The diarrhea is self-limited, so no treatment is required, but hydration with an electrolyte solution (e.g., Powerade) is essential E. Unsure

A. Discontinue pembrolizumab and begin a chemotherapy regimen B. Continue pembrolizumab and add a platinum doublet (cisplatin/pemetrexed) C. Continue pembrolizumab D. Discontinue pembrolizumab and begin tisagenlecleucel E. Unsure

A. It is a monoclonal antibody drug that stimulates the immune system B. It is a monoclonal antibody drug that releases the brakes on the immune system C. It is a monoclonal antibody drug that tags the tumor cells for destruction by the immune system D. It is a monoclonal antibody that downregulates PD-1 expression E. Unsure

A. Immunotherapy causes gastrointestinal toxicity like diarrhea, while chemotherapy does not B. Toxicity onset is NOT closely associated to time of drug administration with immunotherapy C. Chemotherapy is held for grade 3 toxicity and then restarted at the same dose once recovered D. Neutropenia and neutropenic complications are common with all cancer therapy, although the incidence varies E. Unsure

A. Create an infrastructure to ensure patients have timely access to treatment B. Communicate with patients about what to expect and who to contact with questions or concerns, including any toxicity C. Educate staff about how to recognize treatment-related adverse events and promptly get patients treatment D. All of the above E. Unsure